EC
PETX

EcoR1 Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

EcoR1 Capital’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$723K – 51
2017
Q2 		$723K Buy
+100,000
New +$615K 0.13% 36

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

EcoR1 Capital's PETX Position: Q3 2017 in Review

EcoR1 Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 100,000 shares — an estimated $723K sold.

EcoR1 Capital first reported a position in PETX in Q2 2017 and held it in 1 quarter. The position peaked at $723K in Q2 2017. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • EcoR1 Capital reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • EcoR1 Capital sold 100,000 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $723K.
  • EcoR1 Capital first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • EcoR1 Capital's Aratana Therapeutics, Inc. position peaked at $723K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.